Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

Next Previous
Search
Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CREAD
  • Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

  • 20 Jul 2023 Results from CREAD, CREAD2 and Tauriel; assessing assess the additive prognostic value of including baseline [18F]GTP1 tau-PET with the other common predictors presented at the Alzheimer's Association International Conference 2023.
  • 09 Nov 2022 Results from CREAD, CREAD2 and Tauriel; assessing independence in activities of daily living in People With Early Alzheimers Disease, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 19 Sep 2022 Results assessing safety and efficacy of crenezumab in participants with prodromal to mild (early) Alzheimer Disease in two phase 3 studies (CREAD & CREAD2), published in the JAMA Neurology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top